PLX PROTALIX BIOTHERAPEUTICS INC Product Launches 8-K Filing 2023 - Product Launch Protalix BioTherapeutics and Chiesi Global Rare Diseases announced that the European Medicines Agency recommended marketing authorization for PRX-102 for the treatment of Fabry disease.Get access to all SEC 8-K filings of the PROTALIX BIOTHERAPEUTICS INC